Last reviewed · How we verify
ARM B: Blocks Therapy Drug
ARM B: Blocks Therapy Drug is a Beta-blocker Small molecule drug developed by Grupo Argentino de Tratamiento de la Leucemia Aguda. It is currently in Phase 3 development for Acute leukemia (supportive care in phase 3 trial).
ARM B: Blocks Therapy Drug inhibits beta-adrenergic receptors to reduce sympathetic nervous system activity in acute leukemia treatment.
ARM B: Blocks Therapy Drug inhibits beta-adrenergic receptors to reduce sympathetic nervous system activity in acute leukemia treatment. Used for Acute leukemia (supportive care in phase 3 trial).
At a glance
| Generic name | ARM B: Blocks Therapy Drug |
|---|---|
| Sponsor | Grupo Argentino de Tratamiento de la Leucemia Aguda |
| Drug class | Beta-blocker |
| Target | Beta-adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Beta-blockers work by antagonizing beta-adrenergic receptors, thereby decreasing heart rate, blood pressure, and myocardial oxygen demand. In the context of acute leukemia therapy (likely as a supportive care agent), beta-blockade may help manage cardiovascular stress and arrhythmias associated with intensive chemotherapy regimens.
Approved indications
- Acute leukemia (supportive care in phase 3 trial)
Common side effects
- Bradycardia
- Hypotension
- Fatigue
- Dizziness
Key clinical trials
- A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL (PHASE2)
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (PHASE2)
- Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer (PHASE3)
- The Effect of Blood Flow Restriction Training Combined With Transcranial Magnetic Stimulation on Limb Function in Hemiplegic Patients After Stroke (NA)
- A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma (PHASE2)
- EUREKA Study:Phase 2 Study to Optimize Neoadjuvant Therapy in HER2-positive Early-stage Breast Cancer (PHASE2)
- Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC (PHASE2)
- Systems Biological Assessment of Statin Effect on Vaccine Responses (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ARM B: Blocks Therapy Drug CI brief — competitive landscape report
- ARM B: Blocks Therapy Drug updates RSS · CI watch RSS
- Grupo Argentino de Tratamiento de la Leucemia Aguda portfolio CI
Frequently asked questions about ARM B: Blocks Therapy Drug
What is ARM B: Blocks Therapy Drug?
How does ARM B: Blocks Therapy Drug work?
What is ARM B: Blocks Therapy Drug used for?
Who makes ARM B: Blocks Therapy Drug?
What drug class is ARM B: Blocks Therapy Drug in?
What development phase is ARM B: Blocks Therapy Drug in?
What are the side effects of ARM B: Blocks Therapy Drug?
What does ARM B: Blocks Therapy Drug target?
Related
- Drug class: All Beta-blocker drugs
- Target: All drugs targeting Beta-adrenergic receptor
- Manufacturer: Grupo Argentino de Tratamiento de la Leucemia Aguda — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Acute leukemia (supportive care in phase 3 trial)
- Compare: ARM B: Blocks Therapy Drug vs similar drugs
- Pricing: ARM B: Blocks Therapy Drug cost, discount & access